A Gut Signal That Could Shield Hearts from Sleep Apnea

Imagine your gut whispering to your heart while you sleep. Strange notion? Researchers at ASM Microbe 2026 say it may be closer to reality than we thought.

Sleep apnea is more than noisy breathing and daytime fatigue. It repeatedly starves tissues of oxygen, nudges carbon dioxide upward, and sets off a cascade of chemical alarms across the body. Those alarms, it turns out, may include altered bile acids — molecules made by the liver and shaped by the microbes living in our intestines — which then travel through the bloodstream to distant organs.

What if those microbially edited bile acids are not merely bystanders but active players in the way sleep apnea raises cardiovascular risk? That was the question a team led by Celeste Allaband at the University of California, San Diego set out to answer. They focused on a key bile acid receptor called FXR and asked what happens when it is taken out of the equation.

The experiment used two kinds of mice prone to atherosclerosis: one group with the usual FXR receptor and another engineered without it. Both sets were exposed either to normal air or to patterns mimicking obstructive sleep apnea. Fecal samples were collected to track changes in the gut microbiome and the metabolic footprint of the animals, and researchers later examined arterial plaque across multiple blood vessels.

The findings were striking. Mice lacking the FXR receptor accumulated far less plaque in the aorta and aortic arch under sleep-apnea-like conditions. Some plaque still appeared in the pulmonary artery, but the overall burden dropped. And, notably, the gut microbiome and the suite of metabolites it produces showed smaller disturbances when FXR was absent.

Short sentence. Big implication. If gut microbes remodel bile acids that then signal through FXR to promote artery-clogging processes, interrupting that signal could blunt one pathway by which sleep apnea damages the heart.

Researchers identified specific bile acids that seem most relevant and are now planning to interrogate human datasets. The next steps include testing whether supplementing particular bile acids or delivering microbes as targeted probiotics can prevent or reduce disease — or whether direct modulation of FXR could be therapeutic.

Translation from mice to people is never guaranteed. Still, the work opens fresh avenues: bile acids, the FXR receptor, and select gut microbes could become targets for therapies aimed at protecting cardiovascular health in people with sleep apnea.

There is work ahead, but the idea is tantalizing — the gut, acting through a chemical telegram, might be a hidden ally in the fight against sleep apnea’s deadliest consequence.